Tradestie Institutional Equity Comparison Engine

EVMN vs DBVT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EVMN Overall Edge

EVMN Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Evommune, Inc. (EVMN) driven by superior Growth & Margin, Options & Structure while DBVT counters with relative strength in Momentum & Technical. Fundamentally, EVMN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus DBVT at N/M Forward P/E and -5577.0% operating margin (-42.9% YoY). In options structure, EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro) against DBVT sits in SURGE (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
EVMN N/M vs DBVT N/M Fwd P/E
Growth & Margin Winner EVMN
Op Margin 0.0% vs -5577.0% ยท YoY +0.0% vs -42.9%
Momentum & Technical Winner DBVT
1Y -61.0% vs -21.4% ยท 52W Pos 8% vs 9%
Options & Structure Winner EVMN
SURGE (53rd %ile IV) vs SURGE (13th %ile IV)
EVMN US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
1M Return +37.33%
1Y Return -61.03%
Forward P/E N/M
Unified AI Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
DBVT NASDAQ
DBV Technologies S.A.
Biological Products, (No Disgnostic Substances)
$10.27
-6.76% 1D
Market Cap $692.2M
1M Return +13.48%
1Y Return -21.36%
Forward P/E N/M
Unified AI Score
30.9 / 100 SELL
Tech 15.0 Fund 36.0 Flow 60.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EVMN -61.03% DBVT -21.36% Spread: +39.67 pp (DBVT Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period EVMN Revenue DBVT Revenue EVMN Op. Margin DBVT Op. Margin Margin Edge
FY2019 N/A $10M N/A -1162.8% DBVT
FY2020 N/A $10M N/A -1408.7% DBVT
FY2021 N/A $10M N/A -1727.6% DBVT
FY2022 N/A $0M N/A -1994.9% DBVT
FY2023 N/A $20M N/A -486.0% DBVT
FY2024 $10M $0M -1000.2% -2808.7% EVMN
FY2025 $10M $10M -623.6% -2609.2% EVMN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EVMN (3) vs DBVT (4)
Institutional Metric EVMN DBVT Criterion Row Winner
Market Capitalization Scale $315.5M $692.2M Larger Scale DBVT
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -42.9% Higher Growth EVMN
Operating Margin (TTM) Profitability 0.0% -5577.0% Higher Margin EVMN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -69.5% -205.8% Higher ROE EVMN
52-Week Range Position Momentum 8% ($5โ€“$33) 9% ($9โ€“$26) Stronger Trend DBVT
Beta / 30D Volatility Risk Regime 1.05ฮฒ ยท 118% Vol 1.18ฮฒ ยท 77% Vol Lower Realized Risk DBVT
Unified Institutional Score Composite Signal 30.0 / 100 (SELL) 30.9 / 100 (SELL) Higher Composite DBVT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EVMN vs DBVT Buy Guide
EVMN SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 53rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EVMN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DBVT SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live DBVT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EVMN nor DBVT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.